LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 46 filers reported holding LYRA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,865 | +22.1% | 1,500 | +15.9% | 0.00% | – |
| Q2 2023 | $4,802 | +377.8% | 1,294 | +158.8% | 0.00% | – |
| Q1 2023 | $1,005 | -49.8% | 500 | 0.0% | 0.00% | – |
| Q4 2022 | $2,000 | -33.3% | 500 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | +50.0% | 500 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | -60.0% | 500 | -59.5% | 0.00% | – |
| Q4 2021 | $5,000 | -58.3% | 1,234 | 0.0% | 0.00% | – |
| Q3 2021 | $12,000 | -66.7% | 1,234 | -72.2% | 0.00% | – |
| Q2 2021 | $36,000 | -92.7% | 4,434 | -89.6% | 0.00% | -100.0% |
| Q1 2021 | $491,000 | +2788.2% | 42,479 | +2752.9% | 0.00% | – |
| Q4 2020 | $17,000 | +54.5% | 1,489 | +51.0% | 0.00% | – |
| Q3 2020 | $11,000 | -38.9% | 986 | -37.8% | 0.00% | – |
| Q2 2020 | $18,000 | – | 1,586 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $3,572,275 | 0.74% |
| Perceptive Advisors | 9,146,730 | $18,384,927 | 0.54% |
| PURA VIDA INVESTMENTS, LLC | 1,996,972 | $4,013,914 | 0.41% |
| VR Adviser, LLC | 924,170 | $1,857,582 | 0.36% |
| Nantahala Capital Management | 2,220,830 | $4,463,868 | 0.34% |
| Ikarian Capital, LLC | 343,685 | $711,427 | 0.16% |
| Soleus Capital Management, L.P. | 592,417 | $1,190,758 | 0.12% |
| Clearline Capital LP | 119,128 | $239,448 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $303,876 | 0.01% |
| Tower Research Capital LLC (TRC) | 9,972 | $20 | 0.00% |